Case studies of the development of targeted therapies for cancer: 1. BRAF inhibitors in melanoma 2. Autophagy Inhibitors
|
|
- Lesley Lee
- 6 years ago
- Views:
Transcription
1 Case studies of the development of targeted therapies for cancer: 1. BRAF inhibitors in melanoma 2. Autophagy Inhibitors Ravi Amaravadi, MD Assistant Professor of Medicine Division of Hematology-Oncology Department of Medicine Abramson Cancer Center Perelman School of Medicine University of Pennsylvania Disclosures Laboratory Grant Funding NCI Abramson Cancer Center Penn-Pfizer Alliance Millenium Pharmaceuticals Tetralogics Pharmaceuticals Industry Support for clinical trials Advisory Board/Speakers Fee Pfizer Tetralogics Millenium Novartis Roche Roche Merck Bayer Millenium (Takeda) Genentech Patent Pending US 61/177,697 Combination antineoplastic therapy with mtor and autophagy inhibitors US 61/486,641 Novel autophagy inhibitors for cancer therapy 1
2 Case 1: BRAF inhibitors for metastatic melanoma Treatment of Metastatic Melanoma: No standard 1 st Line therapy identified Interferon Interleukin-2 Cisplatin, Vincristine, Dacarbazine Temozolomide High dose temozolomide Tamoxifen v. Dacarbazine Median Survival: 8 months Median Survival Brain Metastases: 3 months 2
3 2010 NCCN guidelines for first line treatment of Stage IV melanoma Clinical trial preferred Or Interleukin 2 Or Dacarbazine Or Temozolomide ± cisplatin and vinblastine 3
4 Ibrahim and Haluska Ann rev. pathology mech. Disease 2009 Suppression of BRAF induces cell death in BRAF mutant cell lines Karasarides et al. Oncogene (2004) 23,
5 Sorafenib Cl CF 3 N H O N H O N O N H Kinase assays IC 50 C-Raf 2 nm mvegfr2, VEGFR3 wt B-Raf, V599E B- Raf 6-10 nm nm p38, PDGFrβ nm FLT-3, c-kit EGFR, PKC, MEK, ERK nm Inactive at 10 mm Wan PT et al. Cell Mar 19;116(6): Sorafenib in Melanoma 2002: phase II trial of sorafenib in melanoma: 2% response rate. 2002: phase I/II trial of sorafenib + carboplatin and paclitaxel 105 patients: 27% response rate/8 month PFS 2005: Sorafenib approved for renal cell ca 2007 Sorafenib approved for HCC : 2009: 2 large randomized phase III trials (n=>1000 patients) of sorafenib + carbo/taxol versus carbo/taxol found absolutely no difference in response rate, or survival with the addition of sorafenib to chemotherapy 5
6 Could targeting BRAF be too simplistic or even misguided? 33,345 mutations were found in the melanoma genome compared to the normal genome from the same patient. 187 mutations were predicted to alter the known function of specific proteins. Nature 463, (14 January 2010) doi: /nature08658; Received 30 July 2009; Accepted 4 November 2009; Published online 16 December 2009; Corrected 14 January 2010 A comprehensive catalogue of somatic mutations from a human cancer genome Erin D. Pleasance 1,8 et al. 6
7 Pharmacodynamics: Does the drug hit its target in patient tumors? Pre-treatment Post-treatment Sorafenib: No PLX4032: Yes 7
8 Phase I Results of PLX4032 in patients with BRAF mutant melanoma Dose and schedule 960 mg bid maximal tolerated dose and phase II dose Safety Common side effects include a rash, squamous cell carcinoma, and fatigue. Response Definition No % Complete response No evidence of disease 1 4 Partial Response Stable Disease Progressive Disease >30% tumor shrinkage from baseline <30% shrinkage and <20% growth from baseline >20% growth from baseline or new tumors (all had shrinkage) Total Day 0 V600E+ melanoma patient PET scan at baseline and day +15 after PLX4032 treatment at 720 mg BID Day 15 Flaherty, ASCO
9 1st interim analysis found that Vemurafenib reduces the risk of progression by 74% and the risk of dying by 63% compared to chemotherapy Chapman et al NEJM 2011 The rapid success and approval of vemurafenib in BRAF mutant melanoma depended on the following: 1) The molecular target was identified and validated in preclinical models 2) The target is present in a large fraction of patients 3) Lessons learned from the failure of the first generation Raf inhibitor sorafenib were used by persistent investigators 4) A more potent and specific second generation inhibitor was found 5) Phase I testing with PK and PD analysis was performed with rigor 6) The phase I dose was increased to the maximal tolerated dose 7) The drug was tested in a biomarker-restricted population (BRAF mutant melanoma) 8) An OPEN collaboration between multiple academic investigators, Pharma teams, and the FDA 9) LUCK 9
10 As Presented at the NCCS Cancer Policy Roundtable Case 2: Autophagy a new therapeutic target in cancer Autophagy, the cell s garbage disposal and built in recycling plant gets rid of waste and feeds the cancer cell when it is faced with stresses. Damaged cell component Autophagic Vesicle Recycled building blocks Lysosome 10
11 Chloroquine derivatives impair the lysosome, blocking the last step of autophagy Autophagy Inhibition augments cancer cell death in the context of Nutrient Limitation Lum et al. Cell 2005 Growth Factor Limitation Lum et al. Cell 2005 P53 activation or Alkylating chemotherapy Amaravadi et al. JCI 2007 Tumorigenesis McLean et al. JCI 2008 HDAC inhibitor Carew et al. Blood 2007 Dormant tumor cells Luo et al. JCI 2008 Akt inhibitor Degtyarev M (Genentech) J Cell Bio 2008 Imatinib Bellodi JCI 2009 Velcade Ding et al. MBC
12 Could chloroquine (CQ) or hydroxychloroquine (HCQ) be used to treat cancer? Chloroquine derivatives used in humans since 1940 s Used for decades for malaria, rheumatoid arthritis Extensive preclinical testing, hundreds of thousands of patients worth of safety data Hydroxychloroquine is a safer drug than chloroquine at high doses Generic drug with no pharmaceutical company interested in marketing for cancer indications Excellent brain penetration Drug Monthly Cost Erbitux $ 9600 Avastin $ Sorafenib $ 5614 Gleevec $ 3816 Herceptin $ 3195 Tarceva $ 2697 Hydroxychloroquine $
13 Other investigators have already tested chloroquine for cancer Randomized phase III trial of RT/carmustine +/- low dose CQ in newly diagnosed Glioma (Brain Tumors) Sotelo, et al. Ann Int. Med Kaplan Meier Analysis of Overall Survival in GBM patients treated on the phase III trial of CQ/carmustine/RT v. placebo/carmustine/rt ( p>0.05) HCQ Trial #1: ABTC 0603: A phase I/II trial of hydroxychloroquine with radiation therapy and concomitant and adjuvant temozolomide in patients with newly diagnosed GBM WK RT TMZ Initiation Cycle Radiation 59.4 Gy/33 fractions Temozolomide 75 mg/m2 po qd PI: Myrna Rosenfeld, MD, PhD Sample Size: Phase I: 6-18 Phase II: 76 80% power to detect a 40% v. 26% 2-year overall survival rate. HCQ Hydroxychloroquine 200 mg po qd MTD Maintenance Cycle: Setting ABTC (15 centers) DAY TMZ HCQ TMZ 150 mg/m 2 po d1-5 HCQ 200 mg po qd MTD 13
14 Condition Intervention Phase Sponsors Collaborators Multiple myeloma HCQ + Bortezomib I/II UPenn, Millenium Brain, central nervous system tumors Adult solid tumors HCQ+ Temozolomide/RT HCQ+ temozolomide I/II I UPenn,,CTEP, NCI UPenn, Schering Adult solid tumors HCQ+ temsirolimus I UPenn, Wyeth Adult Solid Tumors HCQ + Vorinostat Prostate cancer Docetaxel hydroxychloroquine I San Antonio, NCI, Merck ClinicalTrials.go v Identifier NCT NCT NCT NCT NCT Title A Phase I/II Trial of HCQAdded to Bortezomib for Relapsed/Refractory Myeloma A Phase I/II Trial of HCQ in Conjunction with Radiation Therapy and Concurrent and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme A Phase I Study of HCQ in Combination with temozolomide in Patients with Advanced Solid Tumors A Phase I Study of HCQ in Combination with temsirolimus in Patients with Advanced Solid Tumors A phase I pharmacokinetic and Pharmacodynamic Study of Hydroxychloroquine in combination with vorinostat for the treatment of patients with advanced solid tumors II CINJ, NCI NCT A Phase II Study of Docetaxel and Modulation of Autophagy with HCQ for Metastatic Hormone Refractory Prostate Cancer Prostate cancer HCQ II CINJ, NCI NCT Autophagic Cell Death in Patients with Hormone-Dependent Prostate-Specific Antigen Progression after Local Therapy for Prostate Cancer Breast cancer HCQ+ ixabepilone I/II CINJ, NCI NCT Phase I/II Study of Ixabepilone in Combination with the Autophagy Inhibitor HCQ for the Treatment of Patients with Metastatic Breast Cancer Lung cancer HCQ+Bevacizumab carboplatin paclitaxel Advanced cancer HCQ + sunitinib Non-small cell lung cancer HCQ + Gefitinib I/II Singapore, MGH B-cell chronic lymphocytic leukemia Pancreas Cancer HCQ II North Shore Long Island Jewish HCQ+ Gemcitabine I/II CINJ, NCI NCT Modulation of Autophagy with HCQ in Combination with Carboplatin, Paclitaxel and Bevacizumab in Patients with Advanced/Recurrent Non-Small Cell Lung Cancer -A Phase I/II Study I CINJ, NCI NCT Anti-Angiogenic Therapy in Patients with Advanced Malignancies: A Phase I Trial of Sunitinib and HCQ NCT NCT A Phase II with a Lead in Phase I Study to Examine the Tolerability, Safety Profile and Efficacy of HCQ and Gefitinib in Advanced Non- Small Cell Lung Cancer Autophagic Modulation with Phase II Study to Evaluate the Tolerability and Efficacy of Treatment of Previously Untreated B- Cell Chronic Lymphocytic Leukemia (B-CLL) Patients with HCQ I U. Pittsburgh Pending Phase I/II study of Preoperative Gemcitabine in Combination with Oral HCQ in Subjects With Resectable Stage IIb Or III Pancreatic Adenocarcinoma Renal Cancer HCQ IA U. Pittsburgh Pending Neoadjuvant Study of Preoperative HCQ in Patients with Resectable Renal Cell Carcinoma A PBMC samples Baseline 10 Week 3 9 Week * * * * Patient HCQ (Mg/Day) C Pre-treatment 3 wks 800 mg HCQ /TMZ/RT Autophagic vesicles/cell B * Actin P 3W LC3 I LC3 II 2 µm 14
15 A B HCQ concentration (ng/ml) C Estimated peak HCQ concentration (ng/ml) HCQ concentration (ng/ml) HCQ sulfate daily dose (mg) Significant AV accumulation Time on study (hrs) Figure 5. Whole blood hydroxychloroquine (HCQ) concentrations and pharmacodynamic response. (A) Range of HCQ concentrations demonstrates a proportional dose-concentration relationship. (B) HCQ concentrations are maintained over the course of months. (C) Patients with significant AV accumulation had significantly higher estimated peak HCQ concentrations; *p= (A-C) Patients/samples available: 14/45. Population pharmacokinetic modeling indicated data are best described using a onecompartment model with first-order elimination. Encouraging activity of autophagy inhibition combined with mtor inhibition Phase I trial of temsirolimus + HCQ completed dose escalation 27 pts Dose expansion in melanoma patients Safe and tolerable regimen 65% & 73% stable disease rate in solid tumors and melanoma Temsirolimus as a single agent has a 0% stable disease rate in melanoma MVP mean: MVP mean: MVP mean: Baseline Temsirolimus Tem + HCQ Presented at AACR 2011 and SMR
16 Designing a more potent autophagy inhibitor Lys01/Lys05 (water soluble) are novel potent autophagy inhibitors designed by employing first principles of chemistry. Patent was filed April 2011 A few pharmaceutical companies have expressed initial interest Jeffrey Winkler, PhD Merriam Professor of Organic Chemistry Department of Chemistry School of the Arts and Sciences University of Pennsylvania Within 4 hours of treatment Lys05 treatment results in an increased size and number of accumulated autophagic vesicles compared to HCQ PBS HCQ 10 µm Lys05 10 µm 16
17 In vivo autophagy inhibition and antitumor efficacy of Lys05 in 2 different melanoma xenograft mouse models Identifying the molecular target of lysosomal Autophagy inhibitors Step 1:Subtractive chemical proteomics for target identification Active autophagy inhibitor 1 Lys Inactive autophagy inhibitor 1 Lys
18 A biomarker of sensitivity to autophagy inhibition has been identified Autophagy inhibitor Biomarker + - Figure 1. An autophagy inhibitor biomarker Predicts sensitivity to HCQ Figure 2. IHC and serum DNA methylation Assays can detect the candidate biomarker In patient samples Can autophagy inhibitors help cancer patients? 1) Molecular target identified and validated in preclinical models? Not fully- we need to get more specific 2) Is autophagy and a biomarker of sensitivity to autophagy inhibitors present in a large fraction of patients Yes 3) Are first generation autophagy inhibitor trials up and running? Yes 4) Can we find a more potent and specific drug? Yes-early stages 5) Does phase I testing include PK and PD analysis? Yes 6) Are we pushing the dose to the maximal tolerated dose? Not fully done 7) Are we testing the drug in a biomarker-restricted population? Not yet- early stages of biomarker development and validation 8) Is there an OPEN collaboration between multiple academic investigators, Pharma teams, and the FDA? Emerging interest in pharmaceutical companies, but may need to be championed by other causes. 9) LUCK 18
19 Take Home Messages The successful development of vemurafenib for BRAF mutant melanoma can serve as a model For development of other targeted therapies for cancer. Autophagy is an emerging target in cancer that if properly studied could yield multiple drugs that benefit a large subfraction of cancer patients Thank you to all of the patients and families who have participated in clinical research 19
Response and resistance to BRAF inhibitors in melanoma
Response and resistance to BRAF inhibitors in melanoma Keith T. Flaherty, M.D. Massachusetts General Hospital Cancer Center Disclosures Roche/Genentech: consultant GlaxoSmithKline: consultant BRAF mutations
HDAC Inhibitors and PARP inhibitors. Suresh Ramalingam, MD Associate Professor Chief of Thoracic Oncology Emory University School of Medicine
HDAC Inhibitors and PARP inhibitors Suresh Ramalingam, MD Associate Professor Chief of Thoracic Oncology Emory University School of Medicine Histone Acetylation HAT Ac Ac Ac Ac HDAC Ac Ac Ac Ac mrna DACs
Development of Rational Drug Combinations for Oncology Indications - An Industry Perspective
Development of Rational Drug Combinations for Oncology Indications An Industry Perspective Stuart Lutzker, MDPhD Vice President Oncology Early Development Genentech Inc 1 Conventional Oncology Drug Development
A View to the Future: The Development of Targeted Therapy for Melanoma. Michael Davies, M.D., Ph.D.
A View to the Future: Science to Survivorship Symposium September 26, 2009 The Development of Targeted Therapy for Melanoma Michael Davies, M.D., Ph.D. Assistant Professor, Melanoma Medical Oncology How
presentation session & clinical Keith T. Flaherty, M.D. Abramson Cancer Center of the University of Pennsylvania
Melanoma: highlights from the oral presentation session & clinical science symposium at ASCO 2009 Keith T. Flaherty, M.D. Abramson Cancer Center of the University of Pennsylvania Abstracts to be discussed
2016 Year-End Results and Conference Call. March 14, 2017
2016 Year-End Results and Conference Call March 14, 2017 Forward Looking Statement This communication contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform
Title Cancer Drug Phase Status
Clinical Trial Identifier Title Cancer Drug Phase Status NCT01164995 Study With Wee-1 Inhibitor MK-1775 and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer Epithelial Ovarian Cancer
Targeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
A 10-year summary of kinase small molecule research Text mining AACR abstracts (white paper)
A 10-year summary of kinase small molecule research Text mining AACR abstracts (white paper) Approved Kinase Inhibitors September 2014 Sponsored by PamGene www.pamgene.com The Kinase Activity Profiling
Corporate Medical Policy
Corporate Medical Policy BRAF Gene Variant Testing to Select Melanoma or Glioma Patients File Name: Origination: Last CAP Review: Next CAP Review: Last Review: braf_gene_variant_testing_to_select_melanoma_or_glioma_patients_for_targeted_
SUPPLEMENTARY INFORMATION
SUPPLEMENTARY NFORMATON n format provided by Melero et al. (AUGUST 2015) Supplementary nformation S3 Combinations including two or more immunotherapy agents based on PD-1/PD-L1 blockade. (Source: https://clinicaltrials.gov/
Thoracic and head/neck oncology new developments
Thoracic and head/neck oncology new developments Goh Boon Cher Department of Hematology-Oncology National University Cancer Institute of Singapore Research Clinical Care Education Scope Lung cancer Screening
Innovazioni Terapeutiche In Oncologia Dott. Massimo Ghiani A USL N 8 Ospedale A. Businco Oncologia Medica III. Tarceva TM
Innovazioni Terapeutiche In Oncologia Dott. Massimo Ghiani A USL N 8 Ospedale A. Businco Oncologia Medica III Tarceva TM Tarceva TM (erlotinib HCl) High-affinity, reversible inhibitor of HER1/EGFR Tyrosine
Phase II Cancer Trials: When and How
Phase II Cancer Trials: When and How Course for New Investigators August 9-12, 2011 Learning Objectives At the end of the session the participant should be able to Define the objectives of screening vs.
NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT
NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT The NCIC CTG DSMC reviewed the following trials with respect to safety, trial conduct, including
RT +/- Surgery. Concurrent ChemoRT +/- Surgery
Molecular targeted approaches to head and neck cancer Lillian L. Siu Department of Medical Oncology & Hematology Princess Margaret Hospital, University of Toronto Locally Advanced HNSCC Locally Advanced
Combining Stroma-Targeted Therapies with Radiation to Prevent Resistance
Combining Stroma-Targeted Therapies with Radiation to Prevent Resistance Dan G. Duda, DMD, PhD Harvard Medical School New Cancer Targets NCT Conference Sesptember 23, 2013 Conflicts of Interest None Tumor
NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT
NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT The NCIC CTG DSMC reviewed the following trials with respect to safety, trial conduct, including accrual, and
Phase II Cancer Trials: When and How
Phase II Cancer Trials: When and How Course for New Investigators August 21-23, 2013 Acknowledgment Elizabeth Eisenhauer for some slides! Learning Objectives At the end of the session the participant should
Rationale for Multimodality Therapy for High Risk Localized Prostate Cancer
Rationale for Multimodality Therapy for High Risk Localized Prostate Cancer 100 80 60 Cancer Death Rates for Men, US 1930-2002 Rate Per 100,000 Lung William K. Oh, M.D. 40 Stomach Colon & rectum Prostate
EGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
ISPOR 4 th Asia Pacific Conference IP2 Gilberto de Lima Lopes
Health Economic Considerations for Personalized Medicine in Asia: Using Genomic Profiling to Guide Treatment Decisions in Early Breast Cancer Gilberto de Lima Lopes, Jr., M.D., M.B.A Assistant Director
Roche setting the standards of cancer care Oncology Event for Investors, June 19
Roche setting the standards of cancer care Oncology Event for Investors, June 19 Kapil Dhingra, VP Medical Science Developing a drug to the standard of care Superior clinical benefit, resources and time
VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients. September 2018
VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients September 2018 Forward-Looking Statements Any statements contained in this presentation that do not describe historical facts may
Corporate Medical Policy
Corporate Medical Policy BRAF Gene Mutation Testing to Select Melanoma or Glioma Patients File Name: Origination: Last CAP Review: Next CAP Review: Last Review: braf_gene_mutation_testing_to_select_melanoma_or_glioma_patients_for_targeted_
Revolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer September 2013 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results
Selecting the right patients for the right trials.
Selecting the right patients for the right trials. Paul Waring Professor of Pathology University of Melbourne June 21, 2011 RCPA Genetics short course Drug development challenges. Current model of drug
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
ALCHEMIST. Adjuvant Lung Cancer Enrichment Marker Identification And Sequencing Trials
ALCHEMIST Adjuvant Lung Cancer Enrichment Marker Identification And Sequencing Trials What is ALCHEMIST? ALCHEMIST is 3 integrated trials testing targeted therapy in early stage lung cancer: l A151216:
Posters and Presentations
Posters and Presentations June 2017: American Society of Clinical Oncology (ASCO) Annual - Preliminary Correlative Analysis of PD-L1 expression from the SUNRISE Study. View April 2017: American Association
BRAF Gene Mutation Testing To Select Melanoma or Glioma Patients for Targeted Therapy
BRAF Gene Mutation Testing To Select Melanoma or Glioma Patients for Targeted Therapy Policy Number: 2.04.77 Last Review: 12/2017 Origination: 4/2013 Next Review: 12/2018 Policy Blue Cross and Blue Shield
Clinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
Innovations in Immunotherapy - Melanoma. Systemic Therapies October 27, 2018 Charles L. Bane, MD
Innovations in Immunotherapy - Melanoma Systemic Therapies October 27, 2018 Charles L. Bane, MD Melanoma Prognosis Survival at 10 years Stage I: 90% Stage II: 60% Stage III: 40% Stage IV: 10% 2 Indications
Design of Clinical Trials with Molecularly Targeted Therapies. Gilberto Schwartsmann
Design of Clinical Trials with Molecularly Targeted Therapies Gilberto Schwartsmann What are the basics of clinical trial design? Presented By Jordan Berlin at 2016 ASCO Annual Meeting Advances in molecular
Team Progress Updates. SU2C Pancreatic Dream Team: Cutting Off the Fuel Supply: A New Approach in the Treatment of Pancreatic Cancer
SU2C Pancreatic Dream Team: Cutting Off the Fuel Supply: A New Approach in the Treatment of Pancreatic Cancer Cancer of the pancreas is one of the deadliest forms of cancer, with a five-year survival rate
Selective IDO1 Inhibition: Pharmacodynamic and Antitumor Activity of INCB Holly K. Koblish Incyte Corporation
Selective IDO1 Inhibition: Pharmacodynamic and Antitumor Activity of INCB24360 Holly K. Koblish Incyte Corporation Presenter Disclosure Information The following relationships exist related to this presentation:
A Day in the Life of a Breast Cancer Doctor: Integrating Omics to Optimize Patient Outcomes. March 17-18, 2015 New York, NY
A Day in the Life of a Breast Cancer Doctor: Integrating Omics to Optimize Patient Outcomes March 17-18, 2015 New York, NY A Day in the Life of a Breast Cancer Doctor: Integrating Omics to Optimize Patient
Multi-Mechanism Drugs for Oncology and Inflammation. September 2007
Multi-Mechanism Drugs for Oncology and Inflammation September 2007 1 Forward-Looking Statements Statements that are not descriptions of historical facts are forward-looking and subject to risk and uncertainties.
Nexavar in Combination with Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival
Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Phase II Study in Advanced Breast Cancer: Nexavar in Combination with Chemotherapy Demonstrates 74 Percent Improvement
UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA PhD SCHOOL. PhD THESIS
UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA PhD SCHOOL PhD THESIS THE IMPORTANCE OF TUMOR ANGIOGENESIS IN CEREBRAL TUMOR DIAGNOSIS AND THERAPY ABSTRACT PhD COORDINATOR: Prof. univ. dr. DRICU Anica PhD
Enlarge Slides. One Moment Please. Skin Cancer. Thomas Olencki, DO David Carr, MD. Today s Webcast Friday, 09/09/11, Noon
New Features Enlarge Slides Links One Moment Please Chapters Polling Use the email function to let us know what you think One Moment Please Skin Cancer Thomas Olencki, DO David Carr, MD Today s Webcast
Targeted Therapies in Melanoma
Mutations and Targets Targeted Therapies in Melanoma ckit NRAS
BRAF Inhibition in Melanoma
BRAF Inhibition in Melanoma New York City, Mar 22-23, 2013 Bartosz Chmielowski, MD, PhD Assistant Clinical Professor University of California Los Angeles Disclosures Speaker Bureau: BMS, Genentech, Prometheus
2/21/2016. Cancer Precision Medicine: A Primer. Ovarian Cancer Statistics and Standard of Care in 2015 OUTLINE. Background
Cancer Precision Medicine: A Primer Rebecca C. Arend, MD Division of Gyn Oncology OUTLINE Background Where we are Where we have been Where we are going Targeted Therapy in Ovarian Cancer How to Individualized
One Moment Please. Skin Cancer. Today s Webcast Friday, 09/09/11, Noon. David Carr, MD
One Moment Please One Moment Please Skin Cancer Thomas Olencki, DO David Carr, MD Today s Webcast Friday, 09/09/11, Noon 1 New Features Enlarge Slides Links Chapters Polling Use the email function to let
CALGB Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer
CALGB 30610 Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer Jeffrey A. Bogart Department of Radiation Oncology Upstate Medical University Syracuse, NY Small Cell Lung Cancer Estimated 33,000
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
Treatment of Advanced Bladder Cancer, Where We've Been and How to Move Forward
Treatment of Advanced Bladder Cancer, Where We've Been and How to Move Forward Maha Hussain, MD, FACP Professor of Medicine & Urology Co-Leader Prostate/GU Oncology Program Associate Director for Clinical
New targets in endometrial and ovarian cancer
New targets in endometrial and ovarian cancer SAMO Interdisciplinary Workshop on Gynecologic Tumors Luzern, January 16-17, 2016 C. Sessa IOSI Bellinzona Outline New targets in ovarian cancer - Cell cycle
Immunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
Revolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer March 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn's actual results may
We re Reaching Ludicrous Speed: New Immunotherapy Oncology Medications
We re Reaching Ludicrous Speed: New Immunotherapy Oncology Medications Adam Peele, PharmD, BCPS, BCOP Oncology Pharmacy Manager Cone Health Disclosures Merck Pharmaceuticals Speaker s Bureau 1 Objectives
National Horizon Scanning Centre. Bevacizumab (Avastin) for glioblastoma multiforme - relapsed. August 2008
Bevacizumab (Avastin) for glioblastoma multiforme - relapsed August 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Suresh S. Ramalingam, MD Director of Thoracic Oncology Associate Professor Emory University Atlanta,
Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December
Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December 17 2010. 32/10 Imatinib for gastrointestinal stromal tumours (unresectable/metastatic) (update on
Non-Small Cell Lung Cancer:
Non-Small Cell Lung Cancer: Where We Are Today Sila Shalhoub, PharmD PGY2 Oncology Pharmacy Resident Shalhoub.Sila@mayo.edu Pharmacy Grand Rounds September 26, 2017 2017 MFMER slide-1 Objectives Identify
BRAF Gene Variant Testing To Select Melanoma or Glioma Patients for Targeted Therapy
BRAF Gene Variant Testing To Select Melanoma or Glioma Patients for Targeted Therapy Policy Number: 2.04.77 Last Review: 12/2018 Origination: 4/2013 Next Review: 12/2019 Policy Blue Cross and Blue Shield
IOM Workshop on Comparative Oncology Pharmacokinetics in Companion Animal Cancer Studies
IOM Workshop on Comparative Oncology Pharmacokinetics in Companion Animal Cancer Studies Daniel L. Gustafson, Ph.D. Professor Shipley University Chair in Comparative Oncology Director of Basic Research,
New Developments in Thyroid Cancer
New Developments in Thyroid Cancer Eric J. Sherman, MD Professor Vice-Chair for Clinical Operations Chief, Division of Head and Neck Surgery Departments of Otolaryngology, Radiation Oncology, and Immunology
非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和
資料 2 2 非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和 1 Preclinical studies Therapeutic Window: Efficacy/Toxicity Disease Specificity Subtype Specificity Combination: Concurrent/Sequential Therapeutic situation: Response/
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD
CLINICAL TRIALS Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS
The 2010 Gastrointestinal Cancers Symposium Oral Abstract Session: Cancers of the Pancreas, Small Bowel and Hepatobilliary Tract
The 2010 Gastrointestinal Cancers Symposium : Cancers of the Pancreas, Small Bowel and Hepatobilliary Tract Abstract #131: Phase I study of MK 0646 (dalotuzumab), a humanized monoclonal antibody against
Molecular Imaging in the Development of Cancer Therapeutics. Johannes Czernin
Molecular Imaging in the Development of Cancer Therapeutics Johannes Czernin Ahmanson Biological Imaging Division University of California Los Angeles Cancer Statistics Cancer Type 5-year Survival Rate
National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trial design:
Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A PHASE III STUDY OF IRESSA
New Developments in Cancer Treatment. Dulcinea Quintana, MD
New Developments in Cancer Treatment Dulcinea Quintana, MD Mortality Rates Goals of treatment 1 Cure Goal of treatment 2 Prolong life Goals of treatment 3 Improve Quality of Life Goals of treatment 4
Design considerations for Phase II trials incorporating biomarkers
Design considerations for Phase II trials incorporating biomarkers Sumithra J. Mandrekar Professor of Biostatistics, Mayo Clinic Pre-Meeting Workshop Enhancing the Design and Conduct of Phase II Studies
Management of Brain Metastases Sanjiv S. Agarwala, MD
Management of Brain Metastases Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA, USA Incidence (US):
Treatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic Therapy
Women s Empowerment Cancer Advocacy Network (WE CAN) Conference Bucharest, Romania October 2015 Treatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic
National Horizon Scanning Centre. Erlotinib (Tarceva) in combination with bevacizumab for advanced or metastatic non-small cell lung cancer
Erlotinib (Tarceva) in combination with bevacizumab for advanced or metastatic non-small cell lung cancer This technology summary is based on information available at the time of research and a limited
1.Basis of resistance 2.Mechanisms of resistance 3.How to overcome resistance. 13/10/2017 Sara Redaelli
Dott.ssa Sara Redaelli 13/10/2017 1.Basis of resistance 2.Mechanisms of resistance 3.How to overcome resistance Tumor Heterogeneity: Oncogenic Drivers in NSCLC The Promise of Genotype-Directed Therapy
PTAC meeting held on 5 & 6 May (minutes for web publishing)
PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and
NEWS RELEASE Media Contact: Megan Pace Investor Contact: Kathee Littrell Patient Inquiries: Ajanta Horan
NEWS RELEASE Media Contact: Megan Pace 650-467-7334 Investor Contact: Kathee Littrell 650-225-1034 Patient Inquiries: Ajanta Horan 650-467-1741 GENENTECH RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR
IRESSA (Gefitinib) The Journey. Anne De Bock Portfolio Leader, Oncology/Infection European Regulatory Affairs AstraZeneca
IRESSA (Gefitinib) The Journey Anne De Bock Portfolio Leader, Oncology/Infection European Regulatory Affairs AstraZeneca Overview The Drug The Biomarker and Clinical Trials Sampling Lessons Learned The
OMP-305B83: A Novel, Potent DLL4 & VEGF Targeting Bispecific Antibody for the Treatment Of Solid Tumors
OMP-305B83: A Novel, Potent DLL4 & VEGF Targeting Bispecific Antibody for the Treatment Of Solid Tumors Jakob Dupont MD MA CMO, SVP: OncoMed Pharmaceuticals Adjunct Clinical Faculty: Stanford University
Contemporary Management of Glioblastoma
Contemporary Management of Glioblastoma Incidence Rates of Primary Brain Tumors Central Brain Tumor Registry of the United States, 1992-1997 100 Number of Cases per 100,000 Population 10 1 0.1 x I x I
Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
Revolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer June 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results may
Update on Targeted Therapy in Melanoma
Update on Targeted Therapy in Melanoma Seville June 2013 James Larkin FRCP PhD London UK Overview What are the targets in melanoma? BRAF / KIT / NRAS / GNAQ / MEK DNA / microtubules CTLA4 / PD1 / PDL1
METRIC Study Key Eligibility Criteria
The METRIC Study METRIC Study Key Eligibility Criteria The pivotal METRIC Study is evaluating glembatumumab vedotin in patients with gpnmb overexpressing metastatic triple-negative breast cancer (TNBC).
Update on new agents in Gastrointestinal Tumor (GIST)
Update on new agents in Gastrointestinal Tumor (GIST) Albiruni R Abdul Razak Medical Oncology Sarcoma Site Lead Princess Margaret Cancer Centre/Mount Sinai Hospital 21 st October 2017 1 Disclosure Research
Antibody-Drug Conjugates in Glioblastoma Multiforme: Finding Ways Forward
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
Advances in Melanoma
Advances in Melanoma The Blue, the Black and the Ugly 1 Outline History of Melanoma Why be concerned? Skin cancer updates What s old? What s new (and why are Skin Tumor Group med oncs excited again)? What
Revolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer January 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results
An update on systemic treatment of differentiated and medullary thyroid cancers: What to do after RAI
An update on systemic treatment of differentiated and medullary thyroid cancers: What to do after AI Disclosures: clinical trial support: - Exelixis, BI, Bayer, ECOG, TOG, GSK - Actogenix, Proacta, BMS,
Best Practices in the Treatment and Management of Metastatic Melanoma. Melanoma
Best Practices in the Treatment and Management of Metastatic Melanoma Philip Friedlander MD PhD Director of Melanoma Medical Oncology Program Assistant Professor Division of Hematology Oncology Assistant
Crizotinib in addition to Radiotherapy and TMZ in newly diagnosed GBM
Crizotinib in addition to Radiotherapy and TMZ in newly diagnosed GBM Juan M Sepúlveda Sánchez Unidad Multidisciplinar de Neurooncología Hospital 12 de Octubre Madrid GEINO 1402. Phase Ib, open-label,
Identification of BRAF mutations in melanoma lesions with the Roche z480 instrument
Identification of BRAF mutations in melanoma lesions with the Roche z480 instrument Márta Széll IAP, Siófok May 14, 2012 Multifactorial skin diseses: much more frequent then genodermatoses exhibit familial
European consortium study on the availability of anti-neoplastic medicines
European consortium study on the availability of anti-neoplastic medicines Nathan I Cherny Alexandru ENIU, MD, PhD Norman Levan Chair in Humanistic Chair, Emerging Countries Committee Medicine Department
The Clinical Research E-News
The Clinical Research E-News Volume 6: ISSUE 5: June 12, 2014 Jefferson Kimmel Cancer Center Network: For urgent clinical trial questions or assistance please page: 877-656-9004 New Featured Trials Actively
Summary of Research and Writing Activities in Oncology
Summary of Research and Writing Activities in Oncology Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Manuscripts, Posters,
FDA APPROVES HERCEPTIN FOR THE ADJUVANT TREATMENT OF HER2-POSITIVE NODE-POSITIVE BREAST CANCER
NEWS RELEASE Media Contact: Kimberly Ocampo (650) 467-0679 Investor Contact: Sue Morris (650) 225-6523 Advocacy Contact: Ajanta Horan (650) 467-1741 FDA APPROVES HERCEPTIN FOR THE ADJUVANT TREATMENT OF
DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID
DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID RESUMEN DE ARTICULOS THERESA BOLERO 3 NOAH UP-DATE GEPAR SIXTO RADIOTHERAPY EBCTCG CTCs MISCELANEAS Lancet Oncol 2014;
SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS
SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS (Filgrastim, Capecitabine, Imatinib, Dasatinib, Erolotinib, Sunitinib, Pazopanib, Fludarabine, Sorafenib, Crizotinib, Tretinoin, Nilotinib,
ArQule CorporateUpdate
ArQule April 2015 1 ArQule CorporateUpdate Safe Harbor This presentation and other statements by ArQule may contain forwardlooking statements within the meaning of the Private Securities Litigation Reform
I. Diagnosis of the cancer type in CUP
Latest Research: USA I. Diagnosis of the cancer type in CUP II. Outcomes of site-specific therapy of the cancer type in CUP a. Prospective clinical trial b. Retrospective clinical trials 1 Latest Research:
EGFR: fundamenteel en klinisch
EGFR: fundamenteel en klinisch Guido Lammering MAASTRO Clinic Maastricht, NL What is EGFR?? The EGFR some facts 1186 amino acids 170 kda Expressed by all cells of epithelial origin Increased activation
Chemotherapy Treatment Algorithms for Urology Cancer
Chemotherapy Treatment Algorithms for Urology Cancer Chemoradiation for bladder cancer; Chemotherapy algorithm for non TCC bladder cancer Squamous cell carcinoma; Chemotherapy Algorithm for Non Transitional
HER2-Targeted Rx. An Historical Perspective
HER2-Targeted Rx An Historical Perspective Trastuzumab: Front Line Rx for MBC Median 20.3 v. 25.1 mo P = 0.046 HR 0.8 65% of control patients crossed over Slamon D, et al. N Engl J Med, 2001; 344:783 Trastuzumab:Front-line
TARGET A BETTER NOW FORWARD-LOOKING STATEMENTS NASDAQ: IMGN. Current as of January 2018
NASDAQ: IMGN TARGET A BETTER NOW Current as of January 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward looking statements based on management's current expectations. These statements